Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $62.25.

CLDX has been the topic of a number of research analyst reports. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Citigroup initiated coverage on Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Finally, The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock.

Celldex Therapeutics Stock Performance

CLDX opened at $25.39 on Friday. The company’s 50-day simple moving average is $26.38 and its two-hundred day simple moving average is $33.04. Celldex Therapeutics has a 52-week low of $22.93 and a 52-week high of $53.18. The stock has a market capitalization of $1.68 billion, a P/E ratio of -9.88 and a beta of 1.57.

Insider Buying and Selling at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Celldex Therapeutics

Several large investors have recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky raised its position in shares of Celldex Therapeutics by 5.1% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock valued at $1,449,000 after buying an additional 2,070 shares during the last quarter. Geode Capital Management LLC grew its stake in Celldex Therapeutics by 0.4% during the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock valued at $52,372,000 after acquiring an additional 6,557 shares in the last quarter. Barclays PLC increased its holdings in Celldex Therapeutics by 140.7% in the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock valued at $4,431,000 after acquiring an additional 76,207 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its stake in Celldex Therapeutics by 11.5% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 3,146 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Celldex Therapeutics during the 3rd quarter valued at about $1,561,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.